Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 134
interventional 110
Observational 23
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 67
Biological 8
Genetic 7
Other 7
Drug|placebo 6
Drug|Procedure 6
Dietary Supplement 4
Biological|Drug 2
Biological|Dietary Supplement|Drug 1
Drug|Radiation 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 23
Egypt 12
Italy 10
China 5
Greece 4
NA 4
Greece|Italy 3
Indonesia 3
Thailand 3
Brazil 2
Egypt|Lebanon|Oman|Saudi Arabia|Syrian Arab Republic 2
France 2
Iran, Islamic Republic of 2
Lebanon 2
United States|Australia|Thailand 2
United States|Canada 2
Albania 1
Belgium|United States|Canada|France|Germany|Italy|United Kingdom 1
Egypt|Indonesia 1
Egypt|Saudi Arabia 1
France|Greece|Italy|United Kingdom 1
France|Italy 1
Greece|Italy|Lebanon|Thailand|Turkey 1
Hungary 1
Israel 1
Italy|Lebanon|Thailand 1
Italy|Turkey 1
Jamaica|United Kingdom 1
Lebanon|Thailand 1
Netherlands 1
Singapore 1
Turkey 1
United States|Argentina|Belgium|Brazil|Canada|France|Germany|Greece|Italy|Tunisia|Turkey|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|France|Germany|Greece|Israel|Italy|Lebanon|Malaysia|Netherlands|Spain|Sweden|Taiwan|Thailand|Tunisia|Turkey|United Kingdom 1
United States|Australia|Bulgaria|Canada|France|Greece|Israel|Italy|Lebanon|Malaysia|Taiwan|Thailand|Tunisia|Turkey|United Kingdom 1
United States|Australia|Greece|Italy|Lebanon|Thailand|Turkey|United Kingdom 1
United States|Canada|Germany|Italy|United Kingdom 1
United States|France|Germany|Greece|Italy|United Kingdom 1
United States|France|Germany|Italy|Thailand|United Kingdom 1
United States|Germany|Greece|Italy|Thailand|Turkey 1
United States|Greece|Italy|Lebanon|Malaysia|Thailand|Tunisia|Turkey|United Kingdom 1
United States|Greece|Lebanon|Malaysia|Thailand|Tunisia|Turkey|United Kingdom 1
United States|Italy|Thailand|Turkey|United Kingdom 1
United States|Thailand 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 66
2 6
3 5
4 5
5 3
6 5
7 4
8 4
9 3
13 1
15 1
16 1
28 1
31 1
33 1
49 1
73 1
123 1

Phase

Phase Study_Count
Phase 2 36
N/A 24
Phase 4 16
Phase 1/Phase 2 13
Phase 3 11
Phase 1 8
Phase 2/Phase 3 2

Number of Arms

Number_of_Arms Count_of_Studies
1 48
2 37
3 9
4 2
5 1
6 1
8 1
NA 11

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 3.00000 6.00 5 6.0 10.0 18.0000 15.0000
1st Qu. 21.25000 10.00 9 20.0 132.5 43.0000 52.5000
Median 36.50000 10.50 19 38.0 255.0 86.0000 60.0000
Mean 58.27273 24.00 20 62.5 255.0 240.6364 139.3333
3rd Qu. 60.00000 21.25 29 91.0 377.5 421.0000 138.5000
Max. 380.00000 100.00 45 192.0 500.0 665.0000 800.0000

Trial Group Type

group_type Group_Count
Experimental 119
Active Comparator 30
No Intervention 12
NA 11
Placebo Comparator 10
Other 5

Intervention Model

intervention_model Study_Count
Single Group Assignment 49
Parallel Assignment 40
Crossover Assignment 8
NA 8
Sequential Assignment 4
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 96
Supportive Care 6
Prevention 4
Other 2
Health Services Research 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
Israel 4
NA 3
Egypt 2
Thailand 2
United States 2
Canada 1
Greece 1
Greece|Italy|Lebanon|Thailand|Turkey 1
Italy 1
Singapore 1
Taiwan 1
United States|Australia|France|Italy|Thailand 1
United States|Canada 1
United States|Germany|Italy 1
United States|Iran, Islamic Republic of 1

Sites per Study

Site_count Study_Count
1 16
2 2
5 3
8 1
10 1

Enrollment Metrics

Measure Observational
Min 28.000
1st Qu 42.000
Median 80.000
Mean 2341.261
3rd Qu 110.000
Max 30000.000

Observation Model

observational_model Study_Count
Cohort 6
NA 5
Case-Control 3
Case-Only 3
Other 3
Case Control 2
Case-Crossover 1

Time Perspective

time_perspective Study_Count
Prospective 11
Cross-Sectional 6
Retrospective 4
Other 1
NA 1

Registries

Studies by Country

Country Study_Count
NA 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 367
1st Qu 367
Median 367
Mean 367
3rd Qu 367
Max 367

Registry Model

observational_model Study_Count
Case-Only 1

Time Perspective

time_perspective Study_Count
Cross-Sectional 1

Follow-up

target_duration Study_Count
2 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03402191 L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT03402191 Recruiting Tanta University 2023-12-31
NCT03381833 A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia https://ClinicalTrials.gov/show/NCT03381833 Recruiting La Jolla Pharmaceutical Company 2019-10-31
NCT04092205 Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation https://ClinicalTrials.gov/show/NCT04092205 Recruiting EmeraMed 2020-03-30
NCT03311243 Periodontal Therapy in Thalassemia Major Patients https://ClinicalTrials.gov/show/NCT03311243 Completed King Saud University 2017-04-10
NCT03275051 Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL) https://ClinicalTrials.gov/show/NCT03275051 Enrolling by invitation Orchard Therapeutics 2025-12-01
NCT03271541 A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia https://ClinicalTrials.gov/show/NCT03271541 Completed Hoffmann-La Roche 2018-06-29
NCT03207009 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia https://ClinicalTrials.gov/show/NCT03207009 Recruiting bluebird bio 2022-06-30
NCT03171831 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major https://ClinicalTrials.gov/show/NCT03171831 Recruiting First Affiliated Hospital of Guangxi Medical University 2021-12-31
NCT03117192 Zinc Supplementation on Cellular Immunity in Thalassemia Major https://ClinicalTrials.gov/show/NCT03117192 Completed Fakultas Kedokteran Universitas Indonesia 2014-02-01
NCT03101423 Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism https://ClinicalTrials.gov/show/NCT03101423 Active, not recruiting First Affiliated Hospital of Guangxi Medical University 2019-12-31
NCT03095326 Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia https://ClinicalTrials.gov/show/NCT03095326 Completed Fakultas Kedokteran Universitas Indonesia 2014-02-01
NCT02986698 In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) https://ClinicalTrials.gov/show/NCT02986698 Recruiting University of California, San Francisco 2022-02-28
NCT02984475 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major https://ClinicalTrials.gov/show/NCT02984475 Recruiting Cairo University 2018-12-31
NCT02950857 A Study of EPEG in Beta Thalassemia Patients https://ClinicalTrials.gov/show/NCT02950857 Completed Prolong Pharmaceuticals 2017-09-27
NCT02906202 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype https://ClinicalTrials.gov/show/NCT02906202 Active, not recruiting bluebird bio 2022-02-28
NCT02744560 Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C https://ClinicalTrials.gov/show/NCT02744560 Completed Tanta University 2017-12-31
NCT02744547 Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C https://ClinicalTrials.gov/show/NCT02744547 Completed Tanta University 2017-12-31
NCT02744105 Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C https://ClinicalTrials.gov/show/NCT02744105 Completed Tanta University 2017-12-31
NCT02674607 the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children https://ClinicalTrials.gov/show/NCT02674607 Completed Tanta University 2017-10-31
NCT02671695 Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia https://ClinicalTrials.gov/show/NCT02671695 Completed Tanta University 2018-04-30
NCT02604433 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia https://ClinicalTrials.gov/show/NCT02604433 Active, not recruiting Celgene 2017-11-24
NCT02597595 Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major https://ClinicalTrials.gov/show/NCT02597595 Completed Tanta University 2017-10-31
NCT02559648 Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis https://ClinicalTrials.gov/show/NCT02559648 Completed Laikο General Hospital, Athens 2016-12-31
NCT02453477 Gene Therapy for Transfusion Dependent Beta-thalassemia https://ClinicalTrials.gov/show/NCT02453477 Active, not recruiting IRCCS San Raffaele 2019-08-31
NCT02435901 HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity https://ClinicalTrials.gov/show/NCT02435901 Active, not recruiting Northwell Health 2019-01-31
NCT02326597 Decision Aid for Therapeutic Options In Sickle Cell Disease https://ClinicalTrials.gov/show/NCT02326597 Completed Emory University 2017-04-17
NCT02268409 ACE-536 Extension Study - Beta Thalassemia https://ClinicalTrials.gov/show/NCT02268409 Active, not recruiting Acceleron Pharma, Inc. 2020-02-29
NCT02198508 Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients https://ClinicalTrials.gov/show/NCT02198508 Completed China Medical University Hospital 2008-07-31
NCT02179359 Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies https://ClinicalTrials.gov/show/NCT02179359 Recruiting Masonic Cancer Center, University of Minnesota 2020-08-31
NCT02151526 A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease https://ClinicalTrials.gov/show/NCT02151526 Completed bluebird bio 2019-02-26
NCT02105766 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure https://ClinicalTrials.gov/show/NCT02105766 Recruiting National Institutes of Health Clinical Center (CC) 2021-08-31
NCT01284738 Beta-thalassemia and Microparticles https://ClinicalTrials.gov/show/NCT01284738 Completed Assistance Publique Hopitaux De Marseille 2014-02-28
NCT02049450 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. https://ClinicalTrials.gov/show/NCT02049450 Completed Novartis 2016-04-12
NCT04364269 Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia https://ClinicalTrials.gov/show/NCT04364269 Recruiting Vifor (International) Inc. 2021-05-31
NCT01966367 CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01966367 Active, not recruiting Columbia University 2022-01-31
NCT01917708 Bone Marrow Transplant With Abatacept for Non-Malignant Diseases https://ClinicalTrials.gov/show/NCT01917708 Completed Emory University 2019-09-19
NCT00006136 Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia https://ClinicalTrials.gov/show/NCT00006136 Completed Office of Rare Diseases (ORD) NA
NCT01752153 Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major https://ClinicalTrials.gov/show/NCT01752153 Completed Shiraz University of Medical Sciences 2012-09-30
NCT01749540 Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia https://ClinicalTrials.gov/show/NCT01749540 Completed Acceleron Pharma, Inc. 2015-11-30
NCT01745120 A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants https://ClinicalTrials.gov/show/NCT01745120 Completed bluebird bio 2018-02-08
NCT01740531 Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion https://ClinicalTrials.gov/show/NCT01740531 Completed Cerus Corporation 2017-12-21
NCT01709032 Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia https://ClinicalTrials.gov/show/NCT01709032 Completed Children’s Hospital of Philadelphia 2015-08-01
NCT01642758 Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon https://ClinicalTrials.gov/show/NCT01642758 Completed Boston University 2012-11-30
NCT01610297 Post Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01610297 Completed Novartis 2015-10-31
NCT01609595 Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand https://ClinicalTrials.gov/show/NCT01609595 Completed Boston University 2012-11-30
NCT01597765 Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients https://ClinicalTrials.gov/show/NCT01597765 Completed Mahidol University 2011-06-30
NCT01571635 Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. https://ClinicalTrials.gov/show/NCT01571635 Active, not recruiting Celgene 2015-07-02
NCT01395199 Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major https://ClinicalTrials.gov/show/NCT01395199 Completed University of Campinas, Brazil 2015-02-28
NCT04390971 Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia https://ClinicalTrials.gov/show/NCT04390971 Recruiting Institute of Hematology & Blood Diseases Hospital 2021-10-31
NCT04353986 PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders https://ClinicalTrials.gov/show/NCT04353986 Recruiting Ain Shams University 2020-04-30
NCT04292314 Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia https://ClinicalTrials.gov/show/NCT04292314 Recruiting Beni-Suef University 2020-10-31
NCT04260516 The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major https://ClinicalTrials.gov/show/NCT04260516 Completed Beni-Suef University 2019-12-03
NCT04211480 Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells https://ClinicalTrials.gov/show/NCT04211480 Recruiting Shanghai Bioray Laboratory Inc. 2021-05-30
NCT04143724 Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Subjects Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia. https://ClinicalTrials.gov/show/NCT04143724 Recruiting Celgene 2021-12-04
NCT04090268 Precision Exercise in Children With Malignant Hemopathies https://ClinicalTrials.gov/show/NCT04090268 Recruiting University of Milano Bicocca 2021-04-03
NCT04064060 A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials https://ClinicalTrials.gov/show/NCT04064060 Recruiting Celgene 2028-01-24
NCT04054921 Safety Study for Beta Thalassemia Subjects on PTG-300 https://ClinicalTrials.gov/show/NCT04054921 Recruiting Protagonist Therapeutics, Inc. 2021-05-10
NCT04009525 Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study https://ClinicalTrials.gov/show/NCT04009525 Recruiting First Affiliated Hospital of Guangxi Medical University 2022-05-31
NCT03993613 Apotransferrin in Patients With β-thalassemia https://ClinicalTrials.gov/show/NCT03993613 Recruiting Sanquin Plasma Products BV 2020-05-01
NCT03992001 Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients https://ClinicalTrials.gov/show/NCT03992001 Enrolling by invitation Università degli Studi di Ferrara 2019-06-30
NCT03961828 Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus https://ClinicalTrials.gov/show/NCT03961828 Completed Tanta University 2018-12-31
NCT03948737 The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell Membrane Beta-thalassemia Major https://ClinicalTrials.gov/show/NCT03948737 Completed Indonesia University 2017-07-30
NCT03877809 Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients https://ClinicalTrials.gov/show/NCT03877809 Recruiting Rare Partners srl Impresa Sociale 2020-09-30
NCT03802201 Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia https://ClinicalTrials.gov/show/NCT03802201 Recruiting Protagonist Therapeutics, Inc. 2020-08-31
NCT03763656 Pharmacokinetics of Oral Hydroxyurea Solution https://ClinicalTrials.gov/show/NCT03763656 Recruiting Nova Laboratories Limited 2021-01-31
NCT03655678 A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia https://ClinicalTrials.gov/show/NCT03655678 Recruiting Vertex Pharmaceuticals Incorporated 2021-02-28
NCT03653338 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias https://ClinicalTrials.gov/show/NCT03653338 Recruiting University of Pittsburgh 2023-08-01
NCT03637556 Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation https://ClinicalTrials.gov/show/NCT03637556 Recruiting DisperSol Technologies, LLC 2020-07-31
NCT03591575 Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children https://ClinicalTrials.gov/show/NCT03591575 Active, not recruiting Chiesi Canada Corp 2020-11-01
NCT03432364 A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) https://ClinicalTrials.gov/show/NCT03432364 Active, not recruiting Sangamo Therapeutics 2021-03-31
NCT01224496 Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders https://ClinicalTrials.gov/show/NCT01224496 Completed Singapore General Hospital 2011-08-31
NCT01206075 Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major https://ClinicalTrials.gov/show/NCT01206075 Completed University of Washington 2012-12-31
NCT01186419 Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload https://ClinicalTrials.gov/show/NCT01186419 Completed Shire 2012-12-31
NCT01140321 Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI https://ClinicalTrials.gov/show/NCT01140321 Completed Ente Ospedaliero Ospedali Galliera 2010-05-31
NCT01125254 Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major https://ClinicalTrials.gov/show/NCT01125254 Completed University of Campinas, Brazil 2011-07-31
NCT01049854 CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant https://ClinicalTrials.gov/show/NCT01049854 Completed New York Medical College 2017-11-30
NCT01039636 Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload https://ClinicalTrials.gov/show/NCT01039636 Completed FerroKin BioSciences, Inc. 2010-12-31
NCT00809042 Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia https://ClinicalTrials.gov/show/NCT00809042 Completed Shiraz University of Medical Sciences 2007-11-30
NCT03851055 Zinc Supplementation in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus https://ClinicalTrials.gov/show/NCT03851055 Completed Ain Shams University 2018-07-10
NCT01639690 ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene https://ClinicalTrials.gov/show/NCT01639690 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-07-31
NCT03889977 Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin https://ClinicalTrials.gov/show/NCT03889977 Completed University of Thessaly 2019-08-30
NCT00790127 Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia https://ClinicalTrials.gov/show/NCT00790127 Completed HemaQuest Pharmaceuticals Inc. 2010-05-31
NCT00749515 Pilot Study for Patients With Poor Response to Deferasirox https://ClinicalTrials.gov/show/NCT00749515 Completed Boston Children’s Hospital 2008-10-31
NCT00800761 Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major https://ClinicalTrials.gov/show/NCT00800761 Completed Ospedale Microcitemico 2006-06-30
NCT00733811 Efficacy Study of the Use of Sequential DFP-DFO Versus DFP https://ClinicalTrials.gov/show/NCT00733811 Completed Azienda Ospedaliera V. Cervello 2008-01-31
NCT00661726 Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia https://ClinicalTrials.gov/show/NCT00661726 Completed HealthCore-NERI 2010-05-31
NCT00658385 Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major https://ClinicalTrials.gov/show/NCT00658385 Completed Memorial Sloan Kettering Cancer Center 2011-02-28
NCT00564941 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload https://ClinicalTrials.gov/show/NCT00564941 Completed Novartis 2011-07-31
NCT00560820 Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload https://ClinicalTrials.gov/show/NCT00560820 Completed Novartis 2012-04-30
NCT00456690 Endocrine and Nutritional Assessment in B Thalassemia Major https://ClinicalTrials.gov/show/NCT00456690 Completed HaEmek Medical Center, Israel 2014-12-31
NCT00447694 Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment https://ClinicalTrials.gov/show/NCT00447694 Completed Novartis 2009-11-30
NCT00408447 Stem Cell Transplant in Sickle Cell Disease and Thalassemia https://ClinicalTrials.gov/show/NCT00408447 Active, not recruiting Columbia University 2019-08-06
NCT00390858 A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. https://ClinicalTrials.gov/show/NCT00390858 Completed Novartis 2008-02-29
NCT00336362 Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major https://ClinicalTrials.gov/show/NCT00336362 Completed University of Washington 2010-08-31
NCT00879242 Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec https://ClinicalTrials.gov/show/NCT00879242 Completed Novartis 2011-05-31
NCT00171301 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) https://ClinicalTrials.gov/show/NCT00171301 Completed Novartis 2008-05-31
NCT00171210 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload https://ClinicalTrials.gov/show/NCT00171210 Completed Novartis 2008-04-30
NCT00171171 A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis https://ClinicalTrials.gov/show/NCT00171171 Completed Novartis 2006-11-30
NCT00105495 Efficacy Study in Removing Excess Iron From the Heart https://ClinicalTrials.gov/show/NCT00105495 Completed ApoPharma NA
NCT00069862 Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia https://ClinicalTrials.gov/show/NCT00069862 Completed Sanofi NA
NCT00061763 Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias https://ClinicalTrials.gov/show/NCT00061763 Completed Novartis 2004-11-30
NCT00061750 Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions https://ClinicalTrials.gov/show/NCT00061750 Completed Novartis 2004-11-30
NCT00029380 Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia https://ClinicalTrials.gov/show/NCT00029380 Completed National Heart, Lung, and Blood Institute (NHLBI) 2006-08-31
NCT00303329 Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients https://ClinicalTrials.gov/show/NCT00303329 Completed Novartis 2008-10-31
NCT00005934 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia https://ClinicalTrials.gov/show/NCT00005934 Completed National Institutes of Health Clinical Center (CC) NA
NCT00005893 Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders https://ClinicalTrials.gov/show/NCT00005893 Completed Office of Rare Diseases (ORD) NA
NCT00001958 Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia) https://ClinicalTrials.gov/show/NCT00001958 Completed National Institutes of Health Clinical Center (CC) NA
NCT00000595 Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis https://ClinicalTrials.gov/show/NCT00000595 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00000588 Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone https://ClinicalTrials.gov/show/NCT00000588 Completed Case Western Reserve University NA
NCT00004378 Stem Cell Transplantation (SCT) for Genetic Diseases https://ClinicalTrials.gov/show/NCT00004378 Completed National Center for Research Resources (NCRR) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03170245 Adiponectin, IL-6 and hsC-RP in Relation to Carotid Intima-media Thickness in B-thalassemia Patients https://ClinicalTrials.gov/show/NCT03170245 Recruiting Assiut University 2020-07-30
NCT03133169 Erythrocyte Glutamine Level Relation to Pulmonary Hypertension Risk in Beta Thalassemia Major Children https://ClinicalTrials.gov/show/NCT03133169 Completed Assiut University 2019-08-25
NCT02904252 The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital https://ClinicalTrials.gov/show/NCT02904252 Completed Mahidol University 2016-10-31
NCT02633943 Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy https://ClinicalTrials.gov/show/NCT02633943 Enrolling by invitation bluebird bio 2031-03-31
NCT02626689 To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care https://ClinicalTrials.gov/show/NCT02626689 Completed Celgene 2017-01-03
NCT02258997 Hepcidin Levels in Sickle Cell Disease (SCD) https://ClinicalTrials.gov/show/NCT02258997 Completed University of North Carolina, Chapel Hill 2015-09-30
NCT02090699 MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias https://ClinicalTrials.gov/show/NCT02090699 Completed University Health Network, Toronto 2014-05-31
NCT00006138 Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia Major https://ClinicalTrials.gov/show/NCT00006138 Completed Office of Rare Diseases (ORD) NA
NCT01935661 A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients. https://ClinicalTrials.gov/show/NCT01935661 Active, not recruiting HaEmek Medical Center, Israel 2020-12-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01496963 Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia https://ClinicalTrials.gov/show/NCT01496963 Active, not recruiting Ente Ospedaliero Ospedali Galliera 2020-12-31
NCT01443312 Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia https://ClinicalTrials.gov/show/NCT01443312 Completed HaEmek Medical Center, Israel 2014-12-31
NCT04367701 Congenital Heart Surgery in Pediatric Patients With Beta-Thalassemia Major https://ClinicalTrials.gov/show/NCT04367701 Completed Ain Shams University 2019-08-15
NCT04208529 A Long-term Follow-up Study in Subjects Who Received CTX001 https://ClinicalTrials.gov/show/NCT04208529 Enrolling by invitation Vertex Pharmaceuticals Incorporated 2039-09-30
NCT04067258 Choroidal Thickness in Beta-thalassemia Patients https://ClinicalTrials.gov/show/NCT04067258 Completed University Hospital of Patras 2020-03-30
NCT03951818 Observing the Changes of Endocrine and Metabolism in Patients With Thalassemia Major https://ClinicalTrials.gov/show/NCT03951818 Recruiting National Taiwan University Hospital 2020-04-01
NCT01241357 High-Tc Susceptometer to Monitor Transfusional Iron Overload https://ClinicalTrials.gov/show/NCT01241357 Completed Columbia University 2015-10-31
NCT01129076 Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma https://ClinicalTrials.gov/show/NCT01129076 Completed National Institutes of Health Clinical Center (CC) NA
NCT00789516 The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00789516 Completed Mahidol University 2009-03-31
NCT00481221 Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter https://ClinicalTrials.gov/show/NCT00481221 Active, not recruiting HaEmek Medical Center, Israel 2020-12-31
NCT00480506 Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major https://ClinicalTrials.gov/show/NCT00480506 Completed Dana-Farber Cancer Institute 2005-10-31
NCT00159042 Genetic Factors Affecting the Severity of Beta Thalassemia https://ClinicalTrials.gov/show/NCT00159042 Completed Hadassah Medical Organization 2017-07-01
NCT00000623 Thalassemia (Cooley’s Anemia) Clinical Research Network (TCRN) https://ClinicalTrials.gov/show/NCT00000623 Completed HealthCore-NERI NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03947632 Anthropometric Measurements in Children Having Transfusion-dependent Beta Thalassemia https://ClinicalTrials.gov/show/NCT03947632 Completed Aga Khan University 2014-12-31